Price Disclosure Reductions for 2021 April Cycle

Page last updated: 21 December 2020

This summary only includes medicines taking a price disclosure reduction on 1 April 2021. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

  • if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2021 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
  • if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Outcomes for flow-on price disclosure reductions to F2 combination items will be communicated to responsible persons with brands of affected drugs in January 2021.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2020 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2020 will also take the reduction on 1 April 2021 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process.

The date for lodgement of disputes is by 5:00pm AEDT on 8 January 2021

Indicative prices for 1 April 2021(including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published in January 2021.

Final prices for 1 April 2021 reductions (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2021.

Excel version of 2021 April Cycle Outcomes Summary 

2021 April Cycle Outcomes Summary

Legal Instrument Drug
(drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)

Legal Instrument Manner of Administrtaion (MoA)

Legal Instrument Form

Average
AEMP
($)

WAPD
(%)
across a
drug/MoA

WADP -
potential
April '21
PBS Price (AEMP)
($) per
pharmaceutical
item

October '20
AEMP
($)

Percentage difference between October '20 and April '21  PBS prices (AEMP) (%) per
pharmaceutical item

Calculations based on:

OWAPD = all brand data

GWAPD = originator brand data removed for at least one pharmaceutical item




 

Applicable Unadjusted Price Reduction
10% or 30%

 

 

 

[Average AEMP minus WAPD = WADP]

[Difference between October '20
AEMP & WADP = % Difference]

 

 

Anastrozole

Tablet 1 mg

Oral

16.78

31.88

11.43

16.78

31.88%

GWAPD

30

Aripiprazole

Tablet 10 mg

Oral

64.54

22.11

50.27

57.33

12.31%

GWAPD

10

Aripiprazole

Tablet 15 mg

Oral

91.59

22.11

71.34

81.35

12.30%

GWAPD

10

Aripiprazole

Tablet 20 mg

Oral

111.49

22.11

86.84

99.03

12.31%

GWAPD

10

Aripiprazole

Tablet 30 mg

Oral

135.86

22.11

105.82

120.67

12.31%

GWAPD

10

Bivalirudin

Powder for I.V. injection 250 mg (as trifluoroacetate)

Injection

474.81

12.83

413.89

474.81

12.83%

OWAPD

10

Bosentan

Tablet 125 mg (as monohydrate)

Oral

1113.08

44.96

612.64

898.26

31.80%

GWAPD

10

Bosentan

Tablet 62.5 mg (as monohydrate)

Oral

1113.08

44.96

612.64

898.26

31.80%

GWAPD

10

Cefuroxime*

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Oral

8.00

15.13

6.79

8.00

15.13%

GWAPD

10

Cefuroxime*

Tablet 250 mg (as axetil)

Oral

9.38

15.13

7.96

9.38

15.14%

GWAPD

10

Entecavir

Tablet 0.5 mg (as monohydrate)

Oral

121.25

49.05

61.78

72.51

14.80%

GWAPD

10

Entecavir

Tablet 1 mg (as monohydrate)

Oral

197.18

49.05

100.46

117.91

14.80%

GWAPD

10

Ezetimibe

Tablet 10 mg

Oral

17.56

38.33

10.83

12.71

14.79%

Does not meet 30 month clock

10

Filgrastim*

Injection 300 micrograms in 0.5 mL single-use pre-filled syringe

Injection

154.80

44.27

86.27

154.80

44.27%

GWAPD

30

Filgrastim*

Injection 480 micrograms in 0.5 mL single-use pre-filled syringe

Injection

248.15

44.27

138.29

248.15

44.27%

GWAPD

30

Filgrastim*

Injection 480 micrograms in 1.6 mL

Injection

496.31

44.27

276.59

496.31

44.27%

GWAPD

30

Ganciclovir

Powder for I.V. infusion 500 mg (as sodium)

Injection

158.37

16.53

132.19

158.37

16.53%

Does not meet 30 month clock

10

Ibuprofen

Tablet 400 mg

Oral

1.79

16.20

1.50

1.79

16.20%

GWAPD

10

Moxonidine

Tablet 200 micrograms

Oral

7.10

10.39

6.36

7.10

10.42%

Does not meet 30 month clock

10

Moxonidine

Tablet 400 micrograms

Oral

12.10

10.39

10.84

12.10

10.41%

Does not meet 30 month clock

10

Naloxone

Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe

Injection

27.77

19.74

22.29

27.77

19.73%

OWAPD

10

Naloxone

Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule

Injection

31.49

19.74

25.27

31.49

19.75%

OWAPD

10

Nortriptyline

Tablet 10 mg (as hydrochloride)

Oral

4.45

19.77

3.57

4.45

19.78%

GWAPD

10

Nortriptyline

Tablet 25 mg (as hydrochloride)

Oral

5.60

19.77

4.49

5.60

19.82%

GWAPD

10

Olmesartan with amlodipine

Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)

Oral

4.66

11.70

4.11

4.66

11.80%

OWAPD

10

Olmesartan with amlodipine

Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)

Oral

9.60

11.70

8.48

9.60

11.67%

OWAPD

10

Olmesartan with amlodipine

Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)

Oral

8.96

11.70

7.91

8.96

11.72%

OWAPD

10

Pegfilgrastim

Injection 6 mg in 0.6 mL single use pre-filled syringe

Injection

1175.00

70.52

346.39

934.95

62.95%

GWAPD

10

Pregabalin

Capsule 150 mg

Oral

24.02

39.77

14.47

18.42

21.44%

GWAPD

10

Pregabalin

Capsule 25 mg

Oral

7.08

39.77

4.26

5.43

21.55%

GWAPD

10

Pregabalin

Capsule 300 mg

Oral

35.84

39.77

21.59

27.48

21.43%

GWAPD

10

Pregabalin

Capsule 75 mg

Oral

15.66

39.77

9.43

12.01

21.48%

GWAPD

10

Raloxifene

Tablet containing raloxifene hydrochloride 60 mg

Oral

27.35

30.10

19.12

27.35

30.09%

GWAPD

30

Rituximab

Solution for I.V. infusion 100 mg in 10 mL

Injection

479.73

35.27

310.53

388.87

20.15%

Does not meet 30 month clock

10

Rituximab

Solution for I.V. infusion 500 mg in 50 mL

Injection

1199.32

35.27

776.32

972.17

20.15%

Does not meet 30 month clock

10

Rituximab

Solution for subcutaneous injection containing rituximab 1400 mg in 11.7 mL

Injection

1699.12

35.27

1099.84

1699.12

35.27%

Does not meet 30 month clock

10

Rosuvastatin*

Tablet 20 mg (as calcium)

Oral

5.11

30.62

3.55

5.11

30.53%

GWAPD

30

Rosuvastatin*

Tablet 40 mg (as calcium)

Oral

7.30

30.62

5.06

7.30

30.68%

GWAPD

30

Rosuvastatin*

Tablet 5 mg (as calcium)

Oral

2.45

30.62

1.70

2.45

30.61%

GWAPD

30

Sevelamer

Tablet containing sevelamer carbonate 800 mg

Oral

198.79

10.84

177.24

198.79

10.84%

Does not meet 30 month clock

10

Sevelamer

Tablet containing sevelamer hydrochloride 800 mg

Oral

198.79

10.84

177.24

198.79

10.84%

Does not meet 30 month clock

10

Tenofovir

Tablet containing tenofovir disoproxil fumarate 300 mg

Oral

339.37

41.95

197.00

298.88

34.09%

GWAPD

10

Tenofovir

Tablet containing tenofovir disoproxil maleate 300 mg

Oral

339.37

41.95

197.00

298.88

34.09%

GWAPD

10

Tenofovir

Tablet containing tenofovir disoproxil phosphate 291 mg

Oral

339.37

41.95

197.00

298.88

34.09%

GWAPD

10

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

Oral

92.49

41.82

53.81

92.49

41.82%

OWAPD

10

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg

Oral

92.49

41.82

53.81

92.49

41.82%

OWAPD

10

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg

Oral

92.49

41.82

53.81

92.49

41.82%

OWAPD

10

Teriflunomide

Tablet 14 mg

Oral

628.85

30.95

434.22

511.19

15.06%

Does not meet 30 month clock

10

Tranexamic acid

Tablet 500 mg

Oral

27.14

12.16

23.84

27.14

12.16%

GWAPD

10

Trastuzumab*

Powder for I.V. infusion 150 mg

Injection

533.22

30.05

372.99

470.25

20.68%

Does not meet 30 month clock

10

Trastuzumab*

Powder for I.V. infusion 420 mg

Injection

1493.02

30.05

1044.37

1316.69

20.68%

Does not meet 30 month clock

10

Trastuzumab*

Powder for I.V. infusion 60 mg

Injection

213.29

30.05

149.20

188.10

20.68%

Does not meet 30 month clock

10

Valganciclovir

Tablet 450 mg (as hydrochloride)

Oral

713.52

23.23

547.77

713.52

23.23%

GWAPD

10

Voriconazole

Tablet 200 mg

Oral

726.74

23.56

555.52

726.74

23.56%

GWAPD

10

Voriconazole

Tablet 50 mg

Oral

181.69

23.56

138.88

181.69

23.56%

GWAPD

10